SLGL צמיחת רווח למניה השנה Sol-Gel Technologies

The resilience of Sol-Gel Technologies (SLGL) is based on the competencies of Israeli management in the field of silicon drug delivery. Looking at the annual earnings per share growth on GURU.Markets, where the -252.30 level is the current value, the market's reaction to the human capital potential of the research chemists is evident. However, royalty volatility and R&D expenses create certain financial risks for the company.

This indicator determines the dynamics of earnings per share, reflecting the actual efficiency of the business. By analyzing the annual change in EPS, an investor can see the growth rates of profitability without quarterly gaps. The metric is calculated as the percentage deviation of the current earnings value from the same period last year. For Sol-Gel Technologies (SLGL), this trend depends directly on the commercial success of dermatological products. Growth in this metric confirms the effectiveness of the partnership with Galderma and the successful implementation of silica encapsulation technologies.